OncoMatch/Clinical Trials/NCT05518253
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Is NCT05518253 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CD70 CAR-T cells and CD70 CAR-T cells for metastatic tumor.
Treatment: CD70 CAR-T cells · CD70 CAR-T cells — This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Renal Cell Carcinoma
Ovarian Cancer
Cervical Cancer
Biomarker criteria
Required: CD70 overexpression (IHC 3+)
positive tumor CD70 expression (tumor CD70 positive (IHC 3+) confirmed by histology or pathology)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard treatment
Failure or intolerance after standard treatment (disease progression or intolerance such as surgery, chemotherapy, radiotherapy, targeted therapy, etc.), and there is currently no effective treatment
Cannot have received: anti-CD70 therapy
Received anti-CD70 drug treatment before screening
Lab requirements
Blood counts
neutrophils>1.0×10^9/L, platelets>75×10^9/L, hemoglobin>80g/L
Kidney function
serum creatinine≤2.0×ULN
Liver function
ALT and AST ≤2.0×ULN (≤3.0×ULN with liver tumor infiltration); total bilirubin ≤2.0×ULN (≤3.0×ULN with Gilbert syndrome or liver tumor infiltration)
Cardiac function
echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram
The function of important organs is basically normal: Hematopoietic function: neutrophils>1.0×10^9/L, platelets>75×10^9/L, hemoglobin>80g/L; Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram; Renal function: serum creatinine≤2.0×ULN; Liver function: ALT and AST ≤2.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤3.0×ULN); Total bilirubin ≤2.0×ULN (Gilbert syndrome or combined liver tumor infiltration can be relaxed to ≤3.0×ULN); Oxygen saturation > 92% in non-oxygen state.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify